2016-01-262016-01-262009-10LEME, Fabiola O. Paes et al. Inibição e reversão da agregação plaquetária de eqüinos in vitro com o uso de ketoprofeno, fenilbutazona e flunixim meglumine. Pesquisa Veterinária Brasileira, Rio de Janeiro, v. 29, n. 10, p. 803-808, out. 2009. Disponível em: <http://www.scielo.br/pdf/pvb/v29n10/a05v2910.pdf>. Acesso em: 26 jan. 2016. <http://dx.doi.org/10.1590/S0100-736X2009001000005>.0100-736Xhttps://repositorio.ufpa.br/handle/2011/7056Several diseases may lead to platelet pre-activation and hypercoagulability states in horses. The activity of many drugs against platelet aggregation may, not only contribute to the evaluation of a disease but also its response to the therapy. With the aim to study in vitro prevention and reversion of platelet aggregation, the non steroidal anti-inflammatory drug (NSAID): ketoprophen, phenylbutazone and flunixin-meglumin were evaluated. The comparison demonstrated that phenylbutazone and ketoprophen prevented platelet aggregation induced by ADP better than flunixin-meglumin, in a superior manner to the monoclonal antibody Reopro, and in a better way than the membrane receptor blockers Ro-438857 and RGDS. The reversion of platelet aggregation demonstrated that even phenylbutazone or ketoprophen have a dose-dependent effect.porAcesso AbertoSanguePlaquetasAgregação plaquetáriaAgregometriaEquinoAnti-inflamatóriosArtigo de Periódico